UNSPSC 51181607: Potassium iodide

This classification denotes a radioprotective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1C4QK22F9J. European Medicines Agency schedules Potassium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14985MIG. Potassium iodide generally arises in the molecular formula IK. The term POTASSIUM IODIDE is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule potassium iodide under HS 28276000 and SITC 52329.

As of Q4 2014, POTASSIUM IODIDE remains the US FDA Preferred Term for this commodity. Potassium iodide bears US NLM identifiers UMLS ID C0032831 and NCI Concept Code C47680. SMILES: [K+].[I-].

UNSPSC 51181607 Potassium iodide is a Commodity code covering pharmaceutical-grade potassium iodide products supplied to state and local government facilities through cooperative purchasing frameworks. State and local governments procure this commodity primarily as an OTC pharmaceutical product distributed through established wholesale channels to public health agencies, emergency management departments, and institutional healthcare facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body for this code, managing multi-state pharmaceutical procurement that serves participating states and local government entities across multiple jurisdictions. Potassium iodide solicitations under this code are integrated into broader pharmaceutical RFPs that bundle generic multi-source drugs and OTC products, requiring vendors to meet FDA compliance, current Good Manufacturing Practices (cGMP) certification, and Drug Supply Chain Security Act (DSCSA) requirements. Vendors must maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), submit National Drug Code (NDC) and SKU-level product data, and carry comprehensive insurance including $2,000,000 in professional liability and $5,000,000 in commercial general liability per occurrence.

MMCAP's RFP S1070000015802, posted January 20, 2026 with a due date of March 26, 2026, covers multiple states including Minnesota and Oregon. Evaluation weighs price competitiveness at 75 percent, fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and acceptance of a 3 percent administrative fee (5 percent). The contract term runs two years for new vendors with optional extensions, while incumbent responder amendments extend through June 30, 2028. Products must be marketplace-available by May 15, 2026, with contract effectiveness on July 1, 2026. Pricing formats include flat price, net price (NF30, NF60, NF90), or WAC-minus structures. MMCAP reserves discretion for sole, dual, or multi-awards based on therapeutic considerations and member-specific needs. No specific dollar values or set-aside designations appear in the available documentation.